Phoenix Holdings Ltd. Sells 86,642 Shares of MediWound Ltd. (NASDAQ:MDWD)

Phoenix Holdings Ltd. lowered its stake in MediWound Ltd. (NASDAQ:MDWD) by 69.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 37,351 shares of the biopharmaceutical company’s stock after selling 86,642 shares during the quarter. Phoenix Holdings Ltd. owned about 0.14% of MediWound worth $135,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in MDWD. Meitav Dash Investments Ltd. bought a new position in MediWound in the second quarter valued at approximately $29,000. Marshall Wace LLP acquired a new stake in shares of MediWound in the first quarter valued at approximately $93,000. Thomasville National Bank raised its holdings in shares of MediWound by 68.9% in the third quarter. Thomasville National Bank now owns 38,000 shares of the biopharmaceutical company’s stock valued at $143,000 after purchasing an additional 15,500 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of MediWound by 15.8% in the first quarter. Wells Fargo & Company MN now owns 219,386 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 29,911 shares during the last quarter. Finally, Sargent Investment Group LLC raised its holdings in shares of MediWound by 45.6% in the second quarter. Sargent Investment Group LLC now owns 170,900 shares of the biopharmaceutical company’s stock valued at $569,000 after purchasing an additional 53,500 shares during the last quarter. 16.69% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts have recently issued reports on the stock. TheStreet downgraded shares of MediWound from a “c-” rating to an “e+” rating in a report on Tuesday, September 8th. HC Wainwright reiterated a “buy” rating on shares of MediWound in a report on Friday, August 7th. Finally, BTIG Research assumed coverage on shares of MediWound in a report on Wednesday, September 23rd. They issued a “buy” rating and a $6.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. MediWound has an average rating of “Buy” and a consensus target price of $5.38.

Shares of MDWD opened at $3.80 on Friday. The company has a market cap of $103.40 million, a price-to-earnings ratio of -11.18 and a beta of 1.62. MediWound Ltd. has a 1-year low of $1.44 and a 1-year high of $4.44. The company’s fifty day simple moving average is $3.64 and its 200 day simple moving average is $3.20.

MediWound (NASDAQ:MDWD) last issued its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.07). MediWound had a negative net margin of 48.34% and a negative return on equity of 85.28%. On average, analysts predict that MediWound Ltd. will post -0.4 earnings per share for the current year.

About MediWound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

Recommended Story: What is a good rate of return for a mutual fund?

Want to see what other hedge funds are holding MDWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MediWound Ltd. (NASDAQ:MDWD).

Institutional Ownership by Quarter for MediWound (NASDAQ:MDWD)

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.